Predicting phenotypic severity of uncertain gene variants in the RET proto-oncogene

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Crockett, David K ^a,b   Piccolo, Stephen R ^a   Ridge, Perry G ^b   Margraf, Rebecca L ^b   Lyon, Elaine ^b   Williams, Marc S ^a,c   Mitchell, Joyce A ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

^c INTERMOUNTAIN HEALTHCARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; ARTICLE; BAYES THEOREM; CONTROLLED STUDY; GENE MUTATION; GENETIC ALGORITHM; GENETIC ASSOCIATION; GENETIC VARIABILITY; INTERMETHOD COMPARISON; ONCOGENE RET; PATHOGENICITY; PHENOTYPE; PHYLOGENY; PREDICTION; QUALITY CONTROL; SENSITIVITY AND SPECIFICITY; ALGORITHM; CHEMISTRY; GENETIC PREDISPOSITION; GENETICS; HUMAN; UNCERTAINTY;

PROTEIN RET;

ALGORITHMS; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; PHENOTYPE; PROTO-ONCOGENE PROTEINS C-RET; UNCERTAINTY;

EID: 79953329209     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018380     Document Type: Article

References (28)

1. Weinstein ND, (1999) What does it mean to understand a risk? Evaluating risk comprehension. J Natl Cancer Inst Monogr pp. 15-20.
2. Ensenauer RE, Michels VV, Reinke SS, (2005) Genetic testing: practical, ethical, and counseling considerations. Mayo Clin Proc 80: 63-73.
3. Nowak R, (1994) Genetic testing set for takeoff. Science 265: 464-467.
4. Machens A, Gimm O, Hinze R, Hoppner W, Boehm BO, et al. (2001) Genotype-phenotype correlations in hereditary medullary thyroid carcinoma: oncological features and biochemical properties. J Clin Endocrinol Metab 86: 1104-1109.
5. Ashley EA, Butte AJ, Wheeler MT, Chen R, Klein TE, et al. (2010) Clinical assessment incorporating a personal genome. Lancet 375: 1525-1535.
6. Tchernitchko D, Goossens M, Wajcman H, (2004) In silico prediction of the deleterious effect of a mutation: proceed with caution in clinical genetics. Clin Chem 50: 1974-1978.
7. Wei Q, Wang L, Wang Q, Kruger WD, Dunbrack RL Jr, (2010) Testing computational prediction of missense mutation phenotypes: functional characterization of 204 mutations of human cystathionine beta synthase. Proteins 78: 2058-2074.
8. Kumar P, Henikoff S, Ng PC, (2009) Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 4: 1073-1081.
9. Li B, Krishnan VG, Mort ME, Xin F, Kamati KK, et al. (2009) Automated inference of molecular mechanisms of disease from amino acid substitutions. Bioinformatics 25: 2744-2750.
10. Dorfman R, Nalpathamkalam T, Taylor C, Gonska T, Keenan K, et al. (2010) Do common in silico tools predict the clinical consequences of amino-acid substitutions in the CFTR gene? Clin Genet 77: 464-473.
11. Ferreira-Gonzalez A, Teutsch S, Williams MS, Au SM, Fitzgerald KT, et al. (2008) US system of oversight for genetic testing: a report from the Secretary's Advisory Committee on Genetics, Health and Society. Per Med 5: 521-528.
12. Williams MS, (2009) Quality in clinical genetics. Am J Med Genet C Semin Med Genet 151C: 175-178.
13. Ramensky V, Bork P, Sunyaev S, (2002) Human non-synonymous SNPs: server and survey. Nucleic Acids Res 30: 3894-3900.
14. Ng PC, Henikoff S, (2003) SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res 31: 3812-3814.
15. Ferrer-Costa C, Gelpi JL, Zamakola L, Parraga I, de la Cruz X, et al. (2005) PMUT: a web-based tool for the annotation of pathological mutations on proteins. Bioinformatics 21: 3176-3178.
16. Spencer DS, Stites WE, (1996) The M32L substitution of staphylococcal nuclease: disagreement between theoretical prediction and experimental protein stability. J Mol Biol 257: 497-499.
17. Kang HH, Williams R, Leary J, Ringland C, Kirk J, et al. (2006) Evaluation of models to predict BRCA germline mutations. Br J Cancer 95: 914-920.
18. Engelhardt BE, Jordan MI, Muratore KE, Brenner SE, (2005) Protein molecular function prediction by Bayesian phylogenomics. PLoS Comput Biol 1: e45.
19. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, et al. (1996) The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. Jama 276: 1575-1579.
20. Kouvaraki MA, Shapiro SE, Perrier ND, Cote GJ, Gagel RF, et al. (2005) RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 15: 531-544.
21. Attie T, Pelet A, Edery P, Eng C, Mulligan LM, et al. (1995) Diversity of RET proto-oncogene mutations in familial and sporadic Hirschsprung disease. Hum Mol Genet 4: 1381-1386.
22. Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, et al. (2009) Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19: 565-612.
23. Margraf RL, Crockett DK, Krautscheid PM, Seamons R, Calderon FR, et al. (2009) Multiple endocrine neoplasia type 2 RET protooncogene database: repository of MEN2-associated RET sequence variation and reference for genotype/phenotype correlations. Hum Mutat 30: 548-556.
24. Crockett DK, Piccolo SR, Narus SP, Mitchell JA, Facelli JC, (2010) Computational feature selection and classification of RET phenotypic severity. J Data Mining in Genom Proteomics 1: 1-4.
25. Ng PC, Henikoff S, (2002) Accounting for human polymorphisms predicted to affect protein function. Genome Res 12: 436-446.
26. Sunyaev S, Ramensky V, Koch I, Lathe W III, Kondrashov AS, et al. (2001) Prediction of deleterious human alleles. Hum Mol Genet 10: 591-597.
27. Kawashima S, Kanehisa M, (2000) AAindex: amino acid index database. Nucleic Acids Res 28: 374.
28. Frank E, Hall M, Trigg L, Holmes G, Witten IH, (2004) Data mining in bioinformatics using Weka. Bioinformatics 20: 2479-2481.